Mumbai Capital

USFDA nod for Vyome Bio acne drug

Bio-pharmaceutical company Vyome Biosciences on Thursday said the US Food and Drug Administration (USFDA) has cleared its investigational new drug (IND) to treat moderate-to-severe acne.

“We have received USFDA acceptance of Investigational New Drug application in the US for our lead product VB-1953 to treat moderate-to-severe acne. We plan to start Phase-I clinical trials very soon,” a company statement said here.

“With US FDA accepting our first IND application for the lead program VB-1953, we have become a clinical stage company in US, which is an important value inflection milestone for us.

“This should pave way for further filings with the USFDA in future,” chief executive N Venkat said.

“VB-1953 is a first-in-class new product in Acne therapy for addressing one of the very important and a large unmet need.” —PTI

Our code of editorial values

This article is closed for comments.
Please Email the Editor

Printable version | Jan 22, 2022 5:34:45 PM |

Next Story